<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-21144" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Enterobacter Infections</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ramirez</surname>
            <given-names>Darnelle</given-names>
          </name>
          <aff>St. Lucie Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Giron</surname>
            <given-names>Mariana</given-names>
          </name>
          <aff>HCA</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Darnelle Ramirez declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mariana Giron declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>26</day>
          <month>6</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-21144.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Enterobacter species are responsible for causing many nosocomial infections, and less commonly community-acquired infections, including urinary tract infections (UTI), respiratory infections, soft tissue infections, osteomyelitis, and endocarditis, among many others. This article focuses on the role of the interprofessional team in the evaluation and management of Enterobacter Infections.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the etiology of Enterobacter infections.</p></list-item><list-item><p>Describe the evaluation of Enterobacter infections.</p></list-item><list-item><p>Outline the management options available for Enterobacter Infections.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21144&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21144">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-21144.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p><italic toggle="yes">Enterobacter</italic> is a genus&#x000a0;belonging to the family of&#x000a0;Enterobacteriaceae that is associated primarily with&#x000a0;healthcare-related infections. There are currently 22 species of <italic toggle="yes">Enterobacter. </italic>However, not all species are known to cause human disease. <italic toggle="yes">Enterobacter</italic> species are responsible for causing many nosocomial infections, and less commonly community-acquired infections, including urinary tract infections (UTI), respiratory infections, soft tissue infections, osteomyelitis, and endocarditis, among many others. Certain species of this bacterium&#x000a0;can be part of the microflora&#x000a0;of the mammalian gastrointestinal tract, while other <italic toggle="yes">Enterobacter</italic> species can be present in human skin surfaces, water, certain foods, soil, and sewage.</p>
        <p>Starting in the 1970s, it was acknowledged that the <italic toggle="yes">Enterobacter</italic> species could cause nosocomial infections. According to the National Nosocomial Infections Surveillance System, <italic toggle="yes">Enterobacter</italic> is a common pathogen discovered from respiratory sputum, surgical wounds, and blood found in&#x000a0;isolates from intensive care units (ICU).&#x000a0;</p>
        <p><italic toggle="yes">Enterobacter</italic> has become increasingly resistant to many previously effective antibiotics.&#x000a0;In 2017, the World Health Organization issued a list of antibiotic-resistant bacteria in which carbapenem-resistant Enterobacteriaceae (CRE) was in the critical priority group for an urgent need to develop new antibiotics.<xref ref-type="bibr" rid="article-21144.r1">[1]</xref></p>
      </sec>
      <sec id="article-21144.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p><italic toggle="yes">Enterobacter</italic> is a genus of gram-negative, rod-shaped, facultatively anaerobic bacteria of the&#x000a0;Enterobacteriaceae family. It is also described as non-spore-forming, flagella-containing, urease positive, and lactose fermenting.</p>
        <p>Virulence of this bacterium depends on a variety of factors. Like other gram-negative enteric bacilli, the bacteria use adhesins to bind to host cells. The presence of a lipopolysaccharide (LPS) capsule can aid the bacteria in avoiding opsonophagocytosis. The LPS capsule can initiate a cascade of inflammation in the host cell and may further lead to sepsis.&#x000a0;</p>
        <p>The presence of beta-lactamases in <italic toggle="yes">Enterobacter</italic> spp. is the primary mechanism of antimicrobial resistance. Beta lactamases can hydrolyze the beta-lactam ring seen in penicillin and cephalosporins. The presence of this enzyme has contributed to an increase in the number of resistant <italic toggle="yes">Enterobacter</italic> pathogens.<xref ref-type="bibr" rid="article-21144.r2">[2]</xref></p>
      </sec>
      <sec id="article-21144.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>According to the National Nosocomial Infections Surveillance System, <italic toggle="yes">Enterobacter</italic> spp. was responsible for approximately five to seven percent of hospital-acquired bacteremias in the United States from 1976-1989. Among isolates in the ICU, it was found that <italic toggle="yes">Enterobacter</italic> was the third most common pathogen in the respiratory tract, the fourth most common pathogen in surgical wounds, and the fifth most common pathogen in the urinary tract and the bloodstream.<xref ref-type="bibr" rid="article-21144.r1">[1]</xref></p>
        <p>The Surveillance and Control of Pathogens of Epidemiologic Importance (SCOPE) project analyzed approximately 24,179 cases of nosocomial bloodstream infections in United States Hospitals from 1995-2002. Among monomicrobial bloodstream infections, <italic toggle="yes">Enterobacter</italic> was found in 4.7% of infections in the ICU but only in 3.1% of infections in non-ICU wards. <italic toggle="yes">Enterobacter</italic> spp was the fifth most common pathogen isolated in the ICU, and the eighth-most common pathogen isolated in non-ICU wards.<xref ref-type="bibr" rid="article-21144.r3">[3]</xref></p>
      </sec>
      <sec id="article-21144.s5" sec-type="History and Physical">
        <title>History and Physical</title>
        <p><italic toggle="yes">Enterobacter</italic> infections are associated with an extensive range of clinical manifestations. The most common clinical syndromes are bacteremia, lower respiratory tract infections, UTIs, surgical site infections, and intravascular device-associated infections. Less commonly occurring infections are nosocomial meningitis, sinusitis, and osteomyelitis. <italic toggle="yes">Enterobacter</italic> infections can have very similar clinical presentations as other facultative anaerobic gram-negative rod bacterial infections,&#x000a0;to the point that they can often be indistinguishable.&#x000a0;</p>
        <p><italic toggle="yes">Enterobacter</italic> bacteremia has been widely studied. Fever is the most common presentation in this syndrome, as well as systemic inflammatory response (SIRS), hypotension, shock, and leukocytosis, as seen in many other bloodstream presentations.</p>
        <p><italic toggle="yes">Enterobacter</italic> pneumonia commonly presents with cough, shortness of breath, and consolidations found on a chest x-ray. <italic toggle="yes">Enterobacter</italic> UTI can present with dysuria, frequency, urgency, and positive leukocyte esterase or nitrites on urinalysis.</p>
        <p>Risk factors that predispose to infection include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Prolonged recent use of antimicrobial treatment</p>
          </list-item>
          <list-item>
            <p>Immunocompromised states, particularly malignancy and diabetes</p>
          </list-item>
          <list-item>
            <p>Presence of invasive medical devices&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Admission to the ICU</p>
          </list-item>
          <list-item>
            <p>Recent hospitalization or invasive procedure</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-21144.s6" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>The gold standard for diagnosing <italic toggle="yes">Enterobacter</italic> infections is the utilization of cultures. It is recommended that at least two sets of blood cultures be obtained, one aerobic and one anaerobic bottle. MacConkey agar can be used to determine if the specimen is lactose fermenting. Furthermore, indole testing can be performed to differentiate indole negative <italic toggle="yes">Klebsiella</italic> and <italic toggle="yes">Enterobacter</italic> and indole positive<italic toggle="yes"> E. Coli.</italic>
<italic toggle="yes">Enterobacter</italic> spp are motile, in contrast to <italic toggle="yes">Klebsiella</italic>, which is not motile.</p>
        <p>Other important laboratory studies include:&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Gram stain (may be helpful in the rapid determination of gram-negative rods before cultures are available)</p>
          </list-item>
          <list-item>
            <p>Complete blood count&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Complete metabolic panel</p>
          </list-item>
          <list-item>
            <p>Urinalysis with culture</p>
          </list-item>
        </list>
        <p>Relevant imaging in accordance with the particular organ system involved can be helpful in guiding management.</p>
      </sec>
      <sec id="article-21144.s7" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Antibiotic resistance is a growing problem with regard to treating <italic toggle="yes">Enterobacter</italic> infections. Possible treatments include carbapenems, beta-lactams, beta-lactamase inhibitors, fluoroquinolones, aminoglycosides, and sulfamethoxazole/trimethoprim.</p>
        <p>First and second-generation cephalosporins are generally not effective against <italic toggle="yes">Enterobacter</italic> infections. Although treatment with a third-generation cephalosporin may be effective in some strains of <italic toggle="yes">Enterobacter</italic>,&#x000a0;treatment with third-generation cephalosporins can lead to multiresistant infection.<xref ref-type="bibr" rid="article-21144.r4">[4]</xref>&#x000a0;Third-generation cephalosporins are likely to induce or select derepressed <italic toggle="yes">Enterobacter</italic> genetic variants of AmpC beta-lactamase, leading to the overproduction of the enzyme and developed resistance. The use of third-generation cephalosporins is not recommended in severe <italic toggle="yes">Enterobacter</italic> infections due to increased likelihood of resistance, particularly in <italic toggle="yes">Enterobacter cloacae</italic> and <italic toggle="yes">Enterobacter aerogenes,</italic> two of the most clinically relevant<italic toggle="yes"> Enterobacter </italic>species.&#x000a0;Other mechanisms of resistance include the addition of transferable AmpC gene from plasmids and a mutation in the AmpR repressor.</p>
        <p>Fourth-generation cephalosporins are relatively stable among AmpC beta-lactamases, so they are considered an acceptable treatment option if Extended-Spectrum beta-lactamase (ESBL) is not present.&#x000a0;ESBL enzymes are able to hydrolyze the oxyimino cephalosporins, which may render third and fourth generation cephalosporins ineffective.<xref ref-type="bibr" rid="article-21144.r5">[5]</xref></p>
        <p>Carbapenems have been shown to be the most potent treatments for multidrug-resistant <italic toggle="yes">Enterobacter</italic> infections. Meropenem and Imipenem have been shown to be effective against <italic toggle="yes">E. cloacae</italic> and <italic toggle="yes">E. aerogenes.</italic>&#x000a0;Carbapenems were not generally affected by ESBL in the past. However, resistance has been increasing in recent years. The mechanisms through which <italic toggle="yes">Enterobacter</italic> becomes resistant to carbapenems involve multiple enzymes that are plasmid-mediated, leading to accessible horizontal transfer and development of widespread resistance.</p>
        <p>Possible treatment for&#x000a0;carbapenem-resistant <italic toggle="yes">Enterobacter </italic>(CRE)&#x000a0;includes polymyxins, tigecycline, fosfomycin, and carbapenems (used in a double carbapenem regimen).<xref ref-type="bibr" rid="article-21144.r6">[6]</xref>&#x000a0;Although it may seem paradoxical, the rationale behind a double carbapenem regimen is that one carbapenem operates as the &#x0201c;sacrificial&#x0201d; medication due to its greater affinity to the carbapenemase, so that the concomitant carbapenem with a lesser affinity can maintain a higher concentration.<xref ref-type="bibr" rid="article-21144.r7">[7]</xref> A combination of antimicrobial agents has been shown to be more effective than monotherapy in cases of CRE in which more serious clinical characteristics are seen, such as septic shock and rapidly progressing disease.<xref ref-type="bibr" rid="article-21144.r8">[8]</xref>&#x000a0;</p>
        <p>With regard to CRE bloodstream infections, a combination&#x000a0;regimen with a backbone of colistin has been&#x000a0;found to be effective. Examples of other drugs that can be used with colistin are carbapenems, tigecycline, and fosfomycin. However, resistance to colistin has been increasing in recent years.<xref ref-type="bibr" rid="article-21144.r9">[9]</xref>&#x000a0;It is recommended that colistin-resistant CRE be treated with a combination regimen consisting of a backbone of tigecycline or a combination of two different carbapenems.&#x000a0;Examples of other medications that can be used in conjunction with tigecycline include colistin, fosfomycin, and aminoglycosides. Caution must be taken in those with kidney disease since medications such as colistin and aminoglycosides can cause further kidney damage.<xref ref-type="bibr" rid="article-21144.r10">[10]</xref><xref ref-type="bibr" rid="article-21144.r7">[7]</xref><xref ref-type="bibr" rid="article-21144.r11">[11]</xref></p>
        <p>In CRE UTIs in which patients are not critical, aminoglycosides and fosfomycin are treatments of choice as monotherapy if susceptible.&#x000a0;<xref ref-type="bibr" rid="article-21144.r12">[12]</xref>&#x000a0;Fosfomycin is not recommended for pyelonephritis due to poor oral bioavailability.<xref ref-type="bibr" rid="article-21144.r13">[13]</xref><xref ref-type="bibr" rid="article-21144.r14">[14]</xref>&#x000a0;Tigecycline and colistin are not recommended for CRE UTI due to minimal&#x000a0;urinary excretion. If a patient with a CRE UTI is in a critical state, combination therapy of carbapenem, in addition to colistin or aminoglycoside, is an acceptable treatment option.<xref ref-type="bibr" rid="article-21144.r15">[15]</xref><xref ref-type="bibr" rid="article-21144.r16">[16]</xref></p>
        <p>Once the patient has improved in the inpatient setting, intravenous antibiotics may be switched to oral antibiotics, and treatment can be completed as an outpatient regimen with fluoroquinolones or&#x000a0;sulfamethoxazole/trimethoprim. <italic toggle="yes">Enterobacter</italic> exhibits intrinsic resistance to macrolides due to resistance to the outer cell envelope&#x02019;s low permeability.<xref ref-type="bibr" rid="article-21144.r17">[17]</xref></p>
        <p>Treatment for CRE is highly complex, with a wide degree of variability and requires numerous combinations of medications. Experimental drugs are still being studied as resistance continues to persist. Further discussion regarding treatment is outside the scope of this article.</p>
      </sec>
      <sec id="article-21144.s8" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The differential diagnoses for <italic toggle="yes">Enterobacter</italic> infection include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Sepsis caused by other gram-negative bacilli</p>
          </list-item>
          <list-item>
            <p>Acute respiratory distress syndrome (ARDS)</p>
          </list-item>
          <list-item>
            <p>Aspiration pneumonia or pneumonitis</p>
          </list-item>
          <list-item>
            <p>Pneumonia caused by viruses or other bacteria</p>
          </list-item>
          <list-item>
            <p>Parapneumonic pleural effusion</p>
          </list-item>
          <list-item>
            <p>Lung abscess</p>
          </list-item>
          <list-item>
            <p>Empyema</p>
          </list-item>
          <list-item>
            <p>Urinary tract infections</p>
          </list-item>
          <list-item>
            <p>Bacterial prostatitis</p>
          </list-item>
          <list-item>
            <p>Cellulitis</p>
          </list-item>
          <list-item>
            <p>Osteomyelitis</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-21144.s9" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The mortality rate for <italic toggle="yes">Enterobacter</italic> infections is generally high. A study conducted by Kang et al. that analyzed 30-day mortality rates in <italic toggle="yes">Enterobacter</italic> bacteremia showed that of those receiving appropriate antibiotics, 24.6% died. In those with cephalosporin-resistant strains of <italic toggle="yes">Enterobacter</italic>, 34.7% died.<xref ref-type="bibr" rid="article-21144.r18">[18]</xref> Similar mortality rates have been shown in <italic toggle="yes">Enterobacter</italic> infections in which pneumonia, UTI, and soft tissue infections were the primary clinical manifestation.</p>
      </sec>
      <sec id="article-21144.s10" sec-type="Complications">
        <title>Complications</title>
        <p>All infections from <italic toggle="yes">Enterobacter</italic> spp.&#x000a0;may be complicated by sepsis and septic shock. <italic toggle="yes">Enterobacter</italic> pneumonia can lead to a possible lung abscess, parapneumonic pleural effusion, empyema, or ARDS.</p>
      </sec>
      <sec id="article-21144.s11" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Avoidance of risk factors when possible, such as unnecessary medical devices or inappropriate use of antibiotics, may help prevent&#x000a0;the colonization or worsening of <italic toggle="yes">Enterobacter</italic> infections.</p>
      </sec>
      <sec id="article-21144.s12" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p><italic toggle="yes">Enterobacter</italic> infections are serious infections with a high mortality rate, even with appropriate treatment. The interprofessional team can consist of infectious disease experts, microbiologists, pharmacists, nurses, and physical therapists. Infectious disease experts may help determine appropriate management and&#x000a0;the need for invasive medical devices or catheters. Microbiologists may need to perform specialized tests. Pharmacists may be familiar with the community's antibiogram and also assist the healthcare team in the focus of treatment. Nurses can encourage strict infection control protocols and be aware of medication side effects to inform the rest of the healthcare team. Since many patients who are affected by <italic toggle="yes">Enterobacter</italic> infections are weak and bedridden, physical therapists may also be helpful in their care.</p>
      </sec>
      <sec id="article-21144.s13">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21144&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21144">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/infectious-disease/enterobacter-infections/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=21144">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/21144/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=21144">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-21144.s14">
        <title>References</title>
        <ref id="article-21144.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sanders</surname>
                <given-names>WE</given-names>
              </name>
              <name>
                <surname>Sanders</surname>
                <given-names>CC</given-names>
              </name>
            </person-group>
            <article-title>Enterobacter spp.: pathogens poised to flourish at the turn of the century.</article-title>
            <source>Clin Microbiol Rev</source>
            <year>1997</year>
            <month>Apr</month>
            <volume>10</volume>
            <issue>2</issue>
            <fpage>220</fpage>
            <page-range>220-41</page-range>
            <pub-id pub-id-type="pmid">9105752</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21144.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Davin-Regli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pag&#x000e8;s</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Enterobacter aerogenes and Enterobacter cloacae; versatile bacterial pathogens confronting antibiotic treatment.</article-title>
            <source>Front Microbiol</source>
            <year>2015</year>
            <volume>6</volume>
            <fpage>392</fpage>
            <pub-id pub-id-type="pmid">26042091</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21144.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wisplinghoff</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bischoff</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Tallent</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Seifert</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wenzel</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Edmond</surname>
                <given-names>MB</given-names>
              </name>
            </person-group>
            <article-title>Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study.</article-title>
            <source>Clin Infect Dis</source>
            <year>2004</year>
            <month>Aug</month>
            <day>01</day>
            <volume>39</volume>
            <issue>3</issue>
            <fpage>309</fpage>
            <page-range>309-17</page-range>
            <pub-id pub-id-type="pmid">15306996</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21144.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chow</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Fine</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Shlaes</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Quinn</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Hooper</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>MP</given-names>
              </name>
              <name>
                <surname>Ramphal</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Wagener</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Miyashiro</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>VL</given-names>
              </name>
            </person-group>
            <article-title>Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy.</article-title>
            <source>Ann Intern Med</source>
            <year>1991</year>
            <month>Oct</month>
            <day>15</day>
            <volume>115</volume>
            <issue>8</issue>
            <fpage>585</fpage>
            <page-range>585-90</page-range>
            <pub-id pub-id-type="pmid">1892329</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21144.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rawat</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Nair</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Extended-spectrum &#x003b2;-lactamases in Gram Negative Bacteria.</article-title>
            <source>J Glob Infect Dis</source>
            <year>2010</year>
            <month>Sep</month>
            <volume>2</volume>
            <issue>3</issue>
            <fpage>263</fpage>
            <page-range>263-74</page-range>
            <pub-id pub-id-type="pmid">20927289</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21144.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Suay-Garc&#x000ed;a</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>P&#x000e9;rez-Gracia</surname>
                <given-names>MT</given-names>
              </name>
            </person-group>
            <article-title>Present and Future of Carbapenem-resistant <italic>Enterobacteriaceae</italic> (CRE) Infections.</article-title>
            <source>Antibiotics (Basel)</source>
            <year>2019</year>
            <month>Aug</month>
            <day>19</day>
            <volume>8</volume>
            <issue>3</issue>
            <pub-id pub-id-type="pmid">31430964</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21144.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>White</surname>
                <given-names>BP</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tsui</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chastain</surname>
                <given-names>DB</given-names>
              </name>
            </person-group>
            <article-title>Adding double carbapenem therapy to the armamentarium against carbapenem-resistant Enterobacteriaceae bloodstream infections.</article-title>
            <source>Infect Dis (Lond)</source>
            <year>2019</year>
            <month>Mar</month>
            <volume>51</volume>
            <issue>3</issue>
            <fpage>161</fpage>
            <page-range>161-167</page-range>
            <pub-id pub-id-type="pmid">30663923</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21144.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tzouvelekis</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Markogiannakis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Psichogiou</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tassios</surname>
                <given-names>PT</given-names>
              </name>
              <name>
                <surname>Daikos</surname>
                <given-names>GL</given-names>
              </name>
            </person-group>
            <article-title>Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions.</article-title>
            <source>Clin Microbiol Rev</source>
            <year>2012</year>
            <month>Oct</month>
            <volume>25</volume>
            <issue>4</issue>
            <fpage>682</fpage>
            <page-range>682-707</page-range>
            <pub-id pub-id-type="pmid">23034326</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21144.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tumbarello</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Viale</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Viscoli</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Trecarichi</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Tumietto</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Marchese</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Spanu</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Ambretti</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ginocchio</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Cristini</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Losito</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Tedeschi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cauda</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bassetti</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy.</article-title>
            <source>Clin Infect Dis</source>
            <year>2012</year>
            <month>Oct</month>
            <volume>55</volume>
            <issue>7</issue>
            <fpage>943</fpage>
            <page-range>943-50</page-range>
            <pub-id pub-id-type="pmid">22752516</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21144.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ni</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wei</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Cui</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Tigecycline Treatment for Carbapenem-Resistant Enterobacteriaceae Infections: A Systematic Review and Meta-Analysis.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>95</volume>
            <issue>11</issue>
            <fpage>e3126</fpage>
            <pub-id pub-id-type="pmid">26986165</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21144.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cancelli</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Oliva</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>De Angelis</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mascellino</surname>
                <given-names>MT</given-names>
              </name>
              <name>
                <surname>Mastroianni</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Vullo</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Role of Double-Carbapenem Regimen in the Treatment of Infections due to Carbapenemase Producing Carbapenem-Resistant <italic>Enterobacteriaceae</italic>: A Single-Center, Observational Study.</article-title>
            <source>Biomed Res Int</source>
            <year>2018</year>
            <volume>2018</volume>
            <fpage>2785696</fpage>
            <pub-id pub-id-type="pmid">30581848</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21144.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alexander</surname>
                <given-names>BT</given-names>
              </name>
              <name>
                <surname>Marschall</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tibbetts</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Neuner</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>Dunne</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>Ritchie</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Treatment and clinical outcomes of urinary tract infections caused by KPC-producing Enterobacteriaceae in a retrospective cohort.</article-title>
            <source>Clin Ther</source>
            <year>2012</year>
            <month>Jun</month>
            <volume>34</volume>
            <issue>6</issue>
            <fpage>1314</fpage>
            <page-range>1314-23</page-range>
            <pub-id pub-id-type="pmid">22691610</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21144.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Patel</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Shetty</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Soman</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rodrigues</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Fosfomycin Susceptibility in Urinary Tract Enterobacteriaceae.</article-title>
            <source>J Assoc Physicians India</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>65</volume>
            <issue>9</issue>
            <fpage>14</fpage>
            <page-range>14-16</page-range>
            <pub-id pub-id-type="pmid">29313570</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21144.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Popovic</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Steinort</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Pillai</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Joukhadar</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Fosfomycin: an old, new friend?</article-title>
            <source>Eur J Clin Microbiol Infect Dis</source>
            <year>2010</year>
            <month>Feb</month>
            <volume>29</volume>
            <issue>2</issue>
            <fpage>127</fpage>
            <page-range>127-42</page-range>
            <pub-id pub-id-type="pmid">19915879</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21144.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bates</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Parkins</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hellweg</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gibson</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bugar</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Tigecycline treatment of urinary tract infection and prostatitis: case report and literature review.</article-title>
            <source>Can J Hosp Pharm</source>
            <year>2012</year>
            <month>May</month>
            <volume>65</volume>
            <issue>3</issue>
            <fpage>209</fpage>
            <page-range>209-15</page-range>
            <pub-id pub-id-type="pmid">22783032</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21144.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Satlin</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Kubin</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Blumenthal</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Furuya</surname>
                <given-names>EY</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Jenkins</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Calfee</surname>
                <given-names>DP</given-names>
              </name>
            </person-group>
            <article-title>Comparative effectiveness of aminoglycosides, polymyxin B, and tigecycline for clearance of carbapenem-resistant Klebsiella pneumoniae from urine.</article-title>
            <source>Antimicrob Agents Chemother</source>
            <year>2011</year>
            <month>Dec</month>
            <volume>55</volume>
            <issue>12</issue>
            <fpage>5893</fpage>
            <page-range>5893-9</page-range>
            <pub-id pub-id-type="pmid">21968368</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21144.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tamma</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Conley</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Cosgrove</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Lautenbach</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Amoah</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Avdic</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Tolomeo</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wise</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Subudhi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>JH</given-names>
              </name>
              <collab>Antibacterial Resistance Leadership Group</collab>
            </person-group>
            <article-title>Association of 30-Day Mortality With Oral Step-Down vs Continued Intravenous Therapy in Patients Hospitalized With Enterobacteriaceae Bacteremia.</article-title>
            <source>JAMA Intern Med</source>
            <year>2019</year>
            <month>Mar</month>
            <day>01</day>
            <volume>179</volume>
            <issue>3</issue>
            <fpage>316</fpage>
            <page-range>316-323</page-range>
            <pub-id pub-id-type="pmid">30667477</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21144.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kang</surname>
                <given-names>CI</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>WB</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>HB</given-names>
              </name>
              <name>
                <surname>Oh</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Choe</surname>
                <given-names>KW</given-names>
              </name>
            </person-group>
            <article-title>Bloodstream infections caused by Enterobacter species: predictors of 30-day mortality rate and impact of broad-spectrum cephalosporin resistance on outcome.</article-title>
            <source>Clin Infect Dis</source>
            <year>2004</year>
            <month>Sep</month>
            <day>15</day>
            <volume>39</volume>
            <issue>6</issue>
            <fpage>812</fpage>
            <page-range>812-8</page-range>
            <pub-id pub-id-type="pmid">15472813</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
